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Abstract Enrichment analysis has been widely applied in
the genome-wide association studies, where gene sets
corresponding to biological pathways are examined for
significant associations with a phenotype to help increase
statistical power and improve biological interpretation. In
this work, we expand the scope of enrichment analysis into
brain imaging genetics, an emerging field that studies how
genetic variation influences brain structure and function
measured by neuroimaging quantitative traits (QT). Given
the high dimensionality of both imaging and genetic data,
we propose to study Imaging Genetic Enrichment Analysis
(IGEA), a new enrichment analysis paradigm that jointly
considers meaningful gene sets (GS) and brain circuits
(BC) and examines whether any given GS–BC pair is
enriched in a list of gene–QT findings. Using gene
expression data from Allen Human Brain Atlas and
imaging genetics data from Alzheimer’s Disease Neu-
roimaging Initiative as test beds, we present an IGEA
framework and conduct a proof-of-concept study. This
empirical study identifies 25 significant high-level two-di-
mensional imaging genetics modules. Many of these
modules are relevant to a variety of neurobiological path-
ways or neurodegenerative diseases, showing the promise
of the proposal framework for providing insight into the
mechanism of complex diseases.
Keywords Imaging genetics  Enrichment analysis 
Genome-wide association study  Quantitative trait
1 Introduction
Brain imaging genetics is an emerging field that studies
how genetic variation influences brain structure and func-
tion. Genome-wide association studies (GWAS) have been
performed to identify genetic markers such as single
nucleotide polymorphisms (SNPs) that are associated with
brain imaging quantitative traits (QTs) [20, 21]. Using
biological pathways and networks as prior knowledge,
enrichment analysis has also been performed to discover
pathways or network modules enriched by GWAS findings
to enhance statistical power and help biological interpre-
tation [6]. For example, numerous studies on complex
diseases have demonstrated that genes functioning in the
same pathway can influence imaging QTs collectively even
when constituent SNPs do not show significant association
individually [18]. Enrichment analysis can also help iden-
tify relevant pathways and improve mechanistic under-
standing of underlying neurobiology [7, 11, 15, 19].
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In the genetic domain, enrichment analysis has been
widely studied in gene expression data analysis and has
recently been modified to analyze GWAS data. GWAS-
based enrichment analysis first maps SNP-level scores to
gene-based scores, and then tests whether a pre-defined
gene set S (e.g., a pathway) is enriched in a set of signifi-
cant genes L (e.g., GWAS findings). Two strategies are
often used to compute enrichment significance: threshold-
based [4, 5, 9, 24] and rank-based [23]. Threshold-based
approaches aim to solve an independence test problem
(e.g., chi-square test, hypergeometric test, or binomial z-
test) by treating genes as significant if their scores exceed a
threshold. Rank-based methods take into account the score
of each gene to determine if the members of S are ran-
domly distributed throughout L.
In brain imaging genetics, the above enrichment analy-
sis methods are applicable only to genetic findings asso-
ciated with each single imaging QT. Our ultimate goal is to
discover high-level associations between meaningful gene
sets (GS) and brain circuits (BC), which typically include
multiple genes and multiple QTs. To achieve this goal, we
propose to study Imaging Genetic Enrichment Analysis
(IGEA), a new enrichment analysis paradigm that jointly
considers sets of interest (i.e., GS and BC) in both genetic
and imaging domains and examines whether any given
GS–BC pair is enriched in a list of gene–QT findings.
Using whole brain whole genome gene expression data
from Allen Human Brain Atlas (AHBA) and imaging
genetics data from Alzheimer’s Disease Neuroimaging
Initiative (ADNI) as test beds, we present a novel IGEA
framework and conduct a proof-of-concept study to explore
high-level imaging genetic associations based on brain
wide genome-wide association study (BWGWAS) results.
For consistency purpose, in this paper, we use GS to
indicate a set of genes and BC to indicate a set of regions of
interest (ROIs) in the brain. The proposed framework
consists of the following steps (see also Fig. 1): (1) conduct
BWGWAS on ADNI amyloid imaging genetics data to
identify SNP-QT and gene–QT associations, (2) use AHBA
to identify meaningful GS–BC modules, (3) perform IGEA
to identify GS–BC modules significantly enriched by gene–
QT associations using a threshold-based strategy, and (4)
visualize and interpret the identified GS–BC modules.
2 Methods and materials
We write matrices and vectors as bold uppercase and
lowercase letters, respectively. Given a matrix M ¼ ½mij,
we denote its ith row as mi and jth column as mj. Given
two column vectors a and b, we use corrða; bÞ to denote
their Pearson’s correlation coefficient.
2.1 Brain Wide Genome-Wide Association Study
(BWGWAS)
The imaging and genotyping data used for BWGWAS were
obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). The ADNI
was launched in 2003 as a public–private partnership, led
by Principal Investigator Michael W. Weiner, MD. The
primary goal of ADNI has been to test whether serial
magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment
(MCI) and early Alzheimer’s disease (AD). For up-to-date
information, see http://www.adni-info.org.
Preprocessed [18F]Florbetapir PET scans (i.e., amyloid
imaging data) were downloaded from adni.loni.usc.edu,
then aligned to the corresponding MRI scans and normal-
ized to the Montreal Neurological Institute (MNI) space as
2 2 2 mm voxels. ROI level amyloid measurements
were further extracted based on the MarsBaR AAL atlas.
Genotype data of both ADNI-1 and ADNI-GO/2 phases
were also downloaded, and then quality controlled, impu-
ted, and combined as described in [10]. A total of 980 non-
Hispanic Caucasian participants with both complete amy-
loid measurements and genome-wide data were studied.
Associations between 105 (out of a total 116) baseline
amyloid measures and 5,574,300 SNPs were examined by
performing SNP-based GWAS using PLINK [17] with sex,
age, and education as covariates. To facilitate the subse-
quent enrichment analysis, a gene-based p value was
determined as the smallest p value of all SNPs located in
20 K bp of the gene [14].
2.2 Constructing GS–BC modules using AHBA
There are many types of prior knowledge that can be used
to define meaningful GS and BC entities. In the genomic
domain, the prior knowledge could be based on Gene
Ontology or functional annotation databases; in the imag-
ing domain, the prior knowledge could be neuroanatomic
ontology or brain databases. In this work, to demonstrate
the proposed IGEA framework, we use gene expression
data from the Allen Human Brain Atlas (AHBA, Allen
Institute for Brain Science, Seattle, WA, USA; available
from http://www.brain-map.org/) to extract GS and BC
modules such that genes within a GS share similar
expression profiles and so do ROIs within a BC. We
hypothesize that, given these similar co-expression patterns
across genes and ROIs, each GS–BC pair forms an inter-
esting high-level imaging genetic entity that may be related
to certain biological function and can serve as a valuable
candidate for two-dimensional IGEA.
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The AHBA includes genome-wide microarray-based
expression covering the entire brain through systematic
sampling of regional tissue. Expression profiles for eight
health human brains have been released, including two full
brains and six right hemispheres. One goal of AHBA is to
combine genomics with the neuroanatomy to better
understand the connections between genes and brain
functioning. As an early report indicated that individuals
share as much as 95 % gene expression profile [28], in this
study, we only included one full brain (H0351.2001) to
construct GS–BC modules. First all the brain samples
( 900) were mapped to MarsBaR AAL atlas, which
included 116 brain ROIs. Due to many-to-one mapping
from brain samples to AAL ROIs, there are[1 samples for
each ROI. Following [27], samples located in the same
ROI were merged using the mean statistics. Probes were
then merged to genes using the same strategy. Finally, the
preprocessed gene-ROI profiles were normalized for each
ROI. As a result, the expression matrix contained 16,076
genes over 105 ROIs.
We use E to denote this expression matrix, where ei is
the expression level of gene i across all the 105 ROIs in E,
and ej is the expression profile of ROI j across all the
16,076 genes in E. Given two genes i1 and i2, we use the
Pearson correlation coefficient to define their dissimilarity
dgeneði1; i2Þ as follows:
dgeneði1; i2Þ ¼ 1=2 ð1 corr ððei1ÞT ; ðei2ÞTÞÞ: ð1Þ
Similarly, given two ROIs j1 and j2, we define their dis-
similarity droiðj1; j2Þ as follows:
droiðj1; j2Þ ¼ 1=2 ð1 corr ðej1 ; ej2ÞÞ: ð2Þ
We performed a 2D cluster analysis on E to identify
interesting GS–BC modules. First, we calculated the dis-
tance matrices for both genes and ROIs, using Eqs. (1)
and (2), respectively. Next, two dendrograms were con-
structed by applying hierarchical clustering to two distance
matrices separately, using the UPGMA (Unweighted Pair
Group Method with Arithmetic Mean) algorithm [22].
After that, in the genomic domain, as most enrichment
analyses placed constraints on genetic pathways of sizes
from 10 to 200 [18], we cut the dendrogram at half of its
height to build genetic clusters (i.e., GSs) whose sizes are
mostly within the above range. Finally, in the imaging
domain, we also employed the same parameter to construct
ROI clusters (i.e., BCs).
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Fig. 1 Overview of the proposed Imaging Genetic Enrichment
Analysis (IGEA) framework. A Perform SNP-level GWAS of brain
wide imaging measures. B Map SNP-level GWAS findings to gene-
based. C Construct gene-ROI expression matrix from AHBA data.
D Construct GS–BC modules by performing 2D hierarchical
clustering, and then filter out 2D clusters with an average correlation
below a user-given threshold. E Perform IGEA by mapping gene-
based GWAS findings to the identified GS–BC modules. F For each
enriched GS–BC module, examine the GS using GO terms, KEGG
pathways, and OMIM disease databases, and map the BC to the brain
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Let X be a GS–BC module with n genes and m ROIs,
where xi is the expression level of gene i across all the m
ROIs in X, and xj is the expression profile of ROI j across
all the n genes in X. For each pair of genes in X, i.e.,
ððxi1ÞT ; ðxi2ÞTÞ, we calculate its correlation coefficient. For
each pair of ROIs in X, i.e., ðxj1 ; xj2Þ, we also calculate its
correlation coefficient. After that, we transform each of
these correlation coefficients, say c, to Fisher’s z-statistic
z(c) using the following Eq. (3):
zðcÞ ¼ 1
2
log
1þ c
1 c
 
: ð3Þ
We then define zgeneðXÞ, the gene-based average Fish-
er’s z-statistics of correlation coefficient of X, as follows:
zgeneðXÞ ¼ 2
nðn 1Þ
X
0\i1\i2  n
zðcorr ððxi1ÞTðxi2ÞTÞÞ: ð4Þ
Similarly, we define zroiðXÞ, the ROI-based average
Fisher’s z-statistics of correlation coefficient of X, as
follows:
zroiðXÞ ¼ 2
mðm 1Þ
X
0\j1\j2 m
zðcorr ðxj1 ; xj2ÞÞ: ð5Þ
Based on these average gene-based and ROI-based z-
statistics, respectively, we select the top 20 % of all the
GS–BC modules and include those in our subsequent
analyses, to ensure our studied modules have compara-
tively high co-expression profiles. Thus, in this work, we
focus on the analysis of the following three types of GS–
BC modules with top z-statistics:
1. Gene-based These are the modules with relatively high
co-expression profiles between genes, i.e., zgeneðXÞ is
ranked in the top 20 % of all the zgene scores.
2. ROI-based These are the modules with relatively high
co-expression profiles between ROIs, i.e., zroiðXÞ is
ranked in the top 20 % of all the zroi scores.
3. Gene and ROI-based Both (1) and (2) hold.
2.3 Imaging Genetic Enrichment Analysis (IGEA)
Pathway enrichment analysis has been extensively
employed to genomic domain to analyze the genetic find-
ings associated with a specific imaging QT. In this study,
our goal is to identify high-level associations between gene
sets and brain circuits, which typically include multiple
genes and multiple QTs.
In this study, we propose the threshold-based IGEA by
extending the existing threshold-based enrichment analy-
sis. SNP-level findings have been mapped to gene level
findings in Sect. 2.1. The GWAS findings are a list L of
N ¼ NG  NB gene–QT associations, where we have a set
Gd of NG ¼ jGdj genes and a set Bd of NB ¼ jBdj QTs in
our analysis. From Sect. 2.2, GS–BC modules have been
constructed, where either relevant genes share similar
expression profiles across relevant ROIs, or relevant ROIs
share similar expression profiles across relevant genes, or
both. Given an interesting GS–BC module with gene set Gk
and QT set Bk, IGEA aims to determine whether the target
GS–BC module T ¼ fðg; bÞjg 2 Gd \ Gk; b 2 Bd \ Bkg is
enriched in L.
Now we describe our threshold-based IGEA method.
We have N gene–QT pairs from GWAS. Out of these,
n ¼ jAj pairs (the set A) are significant ones with GWAS p
value passed a certain threshold. We also have m ¼ jPj (the
set P) gene–QT pairs from a given GS–BC module, and k
significant pairs are from P. Using Fisher’s exact test for
independence, the enrichment p value for the given GS–BC
module is calculated as follows:
p-value ¼ PrðjA \ Pj 	 kÞ ¼
X
i	 k
m
i
  Nm
ni
 
N
n
  : ð6Þ
Here, we use PrðÞ to denote the probability function.
2.4 Evaluation of the identified GS–BC modules
For evaluation purpose, we tested the statistical signifi-
cance of the IGEA results. We hypothesize that the gene–
QT associations from BWGWAS of the original data
should be overrepresented in certain GS–BC modules, and
the BWGWAS results on permuted data should not be
enriched in a similar number of GS–BC modules. We
performed the IGEA analysis on n ¼ 50 permuted
BWGWAS results, and estimated the p value for the
number of significant GS–BC modules discovered from the
original data using a t-distribution with n 1 degrees of
freedom.
Given a BWGWAS result R, let Prop(R) be the pro-
portion of modules which are significantly enriched by R.
Let Rorig be the original BWGWAS result, and RpermðiÞ be
the ith permuted BWGWAS result. Let S ¼
fPropðRpermðiÞÞ j 1 i ng be the set of these proportion
values for all the permuted results. Then the p value is
estimated using Eq. (7).
p-value ¼ Pr Tn1	
PropðRorigÞ  lpermﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ 1=np  rperm
 !
: ð7Þ
where Tn1 is the t-distribution with n 1 degrees of
freedom, lperm is the sample mean of S, and rperm is the
sample standard deviation of S.
To determine the functional relevance of the enriched
GS–BC modules, we also tested whether genes from each
module are overrepresented for specific neurobiological
30 X. Yao et al.
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functions, signaling pathways, or complex neurodegener-
ative diseases. We performed pathway enrichment tests
using gene ontology (GO) terms, KEGG pathways and
OMIM (Online Mend-elian Inheritance in Man) database.
3 Results
3.1 Significant GS–BC modules
By performing hierarchical clustering on both genetic and
imaging domains, 171 out of 216 genetic clusters (only
those with size ranging from 10 to 200) and 9 imaging
clusters (with size ranging from 4 to 23, no clusters are
excluded) were identified. 1539 GS–BC modules were
generated by combining each pair of genetic and ROI
clusters. Two sets of 308 (20 % of 1539) modules were
selected according to gene-based and ROI-based z-statis-
tics, respectively. Among them, 90 modules were among
top 20 % in both gene-based and ROI-based ranking
results. We used a moderate size threshold for the selec-
tion, to avoid the exclusion of potentially interesting
candidates.
For the BWGWAS results, we obtained 16; 076
105 ¼ 1; 687; 980 gene–QT associations after mapping
SNP-based p values to genes. Out of these, 1402 gene–QT
associations passed the BWGWAS p value of 1:0e-5.
Figure 2 shows the gene-based GWAS result of an
example QT (i.e., the average amyloid deposition in the
right precuneus). Precuneus amyloid concentration has
been demonstrated to be associated with disordered activity
in Alzheimer’s Disease [8].
Three sets of constructed GS–BC modules (308, 308,
and 90 with top z-statistics using gene-based, ROI-based,
and gene&ROI-based strategies, respectively, see
Sect. 2.2) were tested separately for whether they could be
enriched by BWGWAS results using IGEA. Across three
sets, totally 25 modules turned out to be significant after
Bonferroni correction (see Table 1), of which 15, 17, and 9
are from gene-based, ROI-based, and both gene&ROI-
based categories, respectively. We also tested the signifi-
cance of the number of identified GS–BC modules. Com-
pared to the permuted BWGWAS results, the analysis on
the original data yielded a significantly larger number of
enriched GS–BC modules with estimated p values of
7:6e-25; 1:2e-9, and 1:8e-25, corresponding to gene-based,
ROI-based, and gene&ROI-based strategies, respectively,
indicating that imaging genetic associations existed in
these enriched GS–BC modules.
Across all 25 identified modules, there are 9 and 8
unique GS and BC entities, respectively. Figure 3 shows
the 8 unique identified BCs with corresponding ROI
names, and Fig. 4 maps four of those onto the brain. For
example, BC03 and BC04 include structures that are major
spots for amyloid accumulation in AD (e.g., cingulum,
precuneus). BC05 involves structures responsible for
motivated behaviors (e.g., caudate, pallidum, putamen) and
MYADML (p<1.0E-5)
DIS3L2 (p<1.0E-5)
LINC01013 (p<1.0E-5)
XKR5, DEFB1
GS1-24F4.2
(p<1.0E-5)
WDR72 (p<5.0E-6)TNS3 (p<1.0E-5)
OR51T1, OR51A7
OR51G2, OR51G1
OR51A4, OR51A2
(p<1.0E-5)
NRXN3 
(p<5.0E-6)
AQP9 (p<5.0E-6) LOC102467079
LINC00919
(p<1.0E-5)
C16orf97
(p<1.0E-5)
MIR548X (p<5.0E-6)
PLXDC1, ARL5C
CACNB1, RPL19
(p<5.0E-6)
LOC100507351
(p<1.0E-5)
CBLC (p<5.0E-7)
BCAM (p<5.0E-7)
APOE, APOC1, APOC2
APOC4, APOC1P1, APOC4-AP
CLPTM1, PVRL2, TOMM40
(p<1.0E-34)
Fig. 2 Manhattan plot of imaging quantitative genome-wide associ-
ation for Alzheimer’s Disease individuals based on Precuneus (right)
measurement from amyloid imaging data. The x axis represents the
chromosomes and the y axis represents  log10ðPÞ, where P is the
gene-based significance
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sensory information processing (e.g., thalamus). BC08
involves various frontal regions responsible for executive
functions. Details of all 25 modules are listed in Table 1.
We can find that some modules share common gene sets
with different brain circuits, and some share the same brain
circuits with different gene sets. This illustrates the com-
plex associations among multiple genes and multiple brain
ROIs.
3.2 Pathway analysis of identified GS–BC modules
To explore and analyze functional relevance of our iden-
tified GS–BC modules, we performed pathway enrichment
analysis from three aspects including GO terms, functional
pathways and diseases using Gene Ontology (GO), KEGG
pathways, and OMIM diseases databases, respectively.
Figure 5 shows the KEGG pathway enrichment results
which were mapped to 15 categories. From the results,
most identified GSs had a number of significant functional
enrichments. Several of them were directly related to the
neurodegenerative disease and its development, e.g., Alz-
heimer’s Disease enriched in GS05 and Parkinson’s Dis-
ease enriched in GS01. Another major part of them were
also related to the neurodegenerative diseases and their
development. For instance, caffeine as the most widely
used psychoactive substance, its metabolism (from GS09
located in Module 25) can affect brain metabolism and has
potential benefits on Parkinson’s Disease treatment [16].
There are also several enriched pathways related to
oxidative stress, which is a critical factor for a range of
neurodegenerative disorders. For example, glycolysis and
gluconeogenesis (from GS02 located in Modules 02-07)
Table 1 Twenty-five significantly enriched GS–BC modules from IGEA
Module
ID
Top 20 % Co-
expresseda
BC ID # of
ROIs
GS ID # of
genes
Corrected P value
(gene-based)
Corrected P value
(ROI-based)
Corrected P value
(Gene&ROI-based)
01 Rc BC07 8 GS01 81 – 2.61E06 –
02 G, R, G&Rd BC02 4 GS02 168 9.06E06 9.06E06 9.06E06
03 Gb BC03 11 GS02 168 2.54E11 – –
04 G, R, G&R BC04 5 GS02 168 1.44E06 1.44E06 1.44E06
05 G BC05 14 GS02 168 6.42E06 – –
06 R BC06 13 GS02 168 – 5.91E07 –
07 R BC08 23 GS02 168 – 5.65E22 –
08 G, R, G&R BC01 4 GS03 55 1.38E06 1.38E06 1.38E06
09 G BC02 4 GS03 55 4.39E13 – –
10 R BC04 5 GS03 55 – 1.41E15 –
11 G BC05 14 GS03 55 1.01E14 – –
12 R BC06 13 GS03 55 – 1.72E08 –
13 R BC07 8 GS03 55 – 2.40E21 –
14 R BC07 8 GS04 66 – 4.00E07 –
15 G, R, G&R BC01 4 GS05 19 3.83E05 3.83E05 3.83E05
16 G, R, G&R BC02 4 GS05 19 6.88E09 6.88E09 6.88E09
17 G, R, G&R BC04 5 GS05 19 2.64E10 2.64E10 2.64E10
18 R BC06 13 GS05 19 – 2.26E11 –
19 G, R, G&R BC07 8 GS05 19 1.54E14 1.54E14 1.54E14
20 G, R, G&R BC02 4 GS06 28 4.87E08 4.87E08 4.87E08
21 G BC02 4 GS07 24 7.69E05 – –
22 G&R BC01 4 GS08 33 – – 1.97E04
23 G BC02 4 GS08 33 1.11E07 – –
24 R BC04 5 GS08 33 – 7.39E09 –
25 G BC02 4 GS09 111 4.07E05 – –
See also Sect. 3.2 and Fig. 3 for details about relevant GSs and BCs, respectively
a To indicate whether the top 20 % modules are selected based on the gene-based, ROI-based, or gene&ROI-based strategy
b G: Gene-based
c R: ROI-based
d G&R: Gene&ROI-based
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are associated with hypoxia, ischemia, and AD [2]. Gap
junctions (from GS03 located in Modules 08-13) can
couple various kinds of cells in the central nervous system
(CNS) which play an important role in maintaining normal
function. Signaling transduction, like calcium signaling
pathway (from GS03 located in Modules 08-13) playing
key role in short- and long-term synaptic plasticity has
shown abnormality in many neurodegenerative disorders
including Alzheimer’s Disease, Parkinson’s disease, amy-
otrophic lateral sclerosis (ALS), Huntington’s disease,
spinocerebellar ataxias (SCA), and so on [1].
Table 2 shows the OMIM disease enrichment results.
Several neurodegeneration-related and age-related diseases
and complex disorders were enriched in various gene sets,
such as Alzheimer’s Diease from GS03 and GS05,
Encephalopathy from GS01 and GS02, and Anomalies
from GS05. Besides neurodegeneration diseases and dis-
orders, several cancer-related entities are detected includ-
ing breast cancer from GS02 and leukemia from GS03.
These findings provided potential evidence for the studies
that focused on investigating the relationship between
cancer and neurodegeneration, with abnormal cell growth
and cell loss in common.
Gene Ontology (GO) enrichment indicates the rela-
tionship between identified gene sets and GO terms from
three categories including biological process (BP), cellular
component (CC), and molecular function (MF) (http://gen
eontology.org/). For the GO enrichment of all 9 gene sets,
163 various GO terms were significantly enriched. Top
enriched terms were selected and grouped to 7 categories
including behavior, cell communication, mitochondrion,
metabolic process, neurological system process, response
to stimulus, and signal transduction, as shown in Table 3.
A large number of these terms have direct or indirect
relationships with neurodegenerative diseases or
phenotypes.
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4 Discussion
We have presented a two-dimensional imaging genetic
enrichment analysis (IGEA) framework to explore the
high-level imaging genetic associations by integrating
whole brain genomic, transcriptomic, and neuroanatomic
data. Traditional pathway enrichment analysis focused on
investigating genetic findings of a single phenotype one at
a time, and relationships among imaging QTs could be
ignored. Such approach could be inadequate to provide
insights into the mechanisms of complex diseases that
involve multiple genes and multiple QTs. In this paper, we
have proposed a novel enrichment analysis paradigm IGEA
to detect high-level associations between gene sets and
brain circuits. By jointly considering the complex rela-
tionships between interlinked genetic markers and corre-
lated brain imaging phenotypes, IGEA provides additional
power for extracting biological insights on neurogenomic
associations at a systems biology level. For example, let us
take a look at GS03-BC05, an identified module signifi-
cantly enriched by our GWAS findings. Several ROIs (e.g.,
caudate, pallidum, and putamen) from BC05 have been
indicated responsible for motivated behaviors [3]. Mean-
while both KEGG and GO functional enrichment results of
GS03 show high relevance to behavior and normal function
maintaining (see Fig. 5; Table 3). These observations
suggest that this high-level imaging genetic pattern could
be relevant to the behavior mechanism. It warrants further
investigation to perform analyses targeted at these genes
and ROIs in independent cohorts to better understand the
underlying mechanism from the imaging genetic
perspective.
GS
01
GS
02
GS
03
GS
04
GS
05
GS
06
GS
07
GS
08
GS
09
Atrazine degradation
r
v r
way
way
Neurodegenerativ
Par
Taurine and r
F
r rae inf
v o
Oxidativ rylation
PP way
yeloid leuk
Caff
r
Gene Set
X
X
XX
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Nerv
r
ydr
unity
r
F rting and degradation
Inf rial
Neurodegenerativ
Signal tr
r
r
0 1 2 3 4
Color Key
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Table 2 Top enriched OMIM diseases of identified GSs
GS ID # of gene OMIM Disease P value
GS01 81 Encephalopathy 4.2E2*
Dementia 3.6E2*
GS02 168 Encephalopathy 5.0E2
Breast cancer 9.5E2
GS03 55 Leukemia 2.7E2*
Alzheimer’s disease 8.9E2
GS04 66 Hypertension 5.0E2
GS05 19 Anomalies 2.4E2*
Alzheimer’s disease 4.5E2*
GS06 28 Ectodermal dysplasia 2.0E2*
GS07 24 Hypertension 3.4E2*
Spinocerebellar ataxia 4.3E2*
GS08 33 Glycogen storage disease 1.6E2*
GS09 111 Immunodeficiency 1.4E2*
* Significantly enriched
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The real power of IGEA, however, can be affected by
several aspects. First, the constructed GS–BC modules
should reflect the real relationships among genes as well as
brain ROIs. Thus, it is crucial to define meaningful gene
sets and brain circuits. In our paper, GSs and BCs were
separately extracted from AHBA brain wide expression
data based on hierarchical clustering, which were then
combined to provide GS–BC modules. This strategy was
based on the idea that interlinked genetic markers (or brain
ROIs) would conserve similar expression pattern, i.e.,
would be highly co-expressed. Second, the statistical
measure of enrichment evaluation can be based on different
strategies. We adopted hypergeometric test in our experi-
ment to estimate the over-representation of our defined
GS–BC modules to the list of gene–QT pair.
Based on these two considerations, our proposed para-
digm can be further improved. From our GS–BC module
construction, GSs (or BCs) are clustered together based on
their co-expression pattern across all the ROIs in the whole
brain (or across all the genes in the genome). Although
statistical measures were calculated using Fisher’s
z-transformation to restrict our analyses on only highly co-
expressed modules from our bi-clustering results, we could
be missing other highly co-expressed GSs (or BCs) if they
only had similar expression patterns on a small set of ROIs
(or genes). In other words, our module construction strat-
egy considered the global expression pattern but ignored
the local ones. It is worth for further investigation to try
other reasonable strategies by applying prior knowledge
such as pre-defined genetic pathways/networks or brain
circuits, or by using different co-clustering algorithms
(e.g., [26]) to take into consideration of relevant local
expression patterns.
Hypergeometric test requires a pre-defined threshold to
determine the list of gene–QT pairs. Another limitation is
that it considers only the count of significant gene–QT
pairs, but ignores the strength of gene–QT associations.
There are a number of rank-based enrichment analysis
methods (e.g., GSEA [23]) that can be employed in our
two-dimensional enrichment analysis to overcome these
disadvantages. Another issue is that we used the smallest
SNP-level p value within the gene to represent the gene-
based p value. Therefore, another possible future direction
is to explore other set-based methods for calculating gene-
based p values such as VEGAS [13], GATES [12], and so
on. Besides, from mathematical perspective, associating
Table 3 Top enriched GO terms of GSs from identified GS–BC modules
Group GS ID # of genes GO Category Corrected p value
Behavior GS03 55 Behavior 2.2E2
Learning or memory 4.4E2
Cell communication GS01 81 Regulation of synaptic transmission 2.7E6
Neuron-neuron Synaptic transmission 2.9E3
GS03 55 Synaptic transmission 1.7E4
Metabolic process GS05 19 Fat-soluble vitamin metabolic process 4.3E2
Organic hydroxy compound biosynthetic process 4.8E2
GS06 28 Regulation of translational termination 2.8E2
Mitochondrion GS02 168 Mitochondrial membrane part 2.5E3
Mitochondrial respiratory chain complex I 4.9E3
Neurological system process GS03 55 Associative learning 1.1E2
Learning 4.5E6
GS09 111 Detection of chemical stimulus involved in sensory perception 1.1E4
Olfactory receptor activity 1.9E5
Response to stimulus GS03 55 Response to amphetamine 2.0E3
Visual behavior 4.5E3
GS05 19 Response to cholesterol 3.6E2
Response to sterol 3.7E2
GS09 111 Detection of chemical stimulus 1.6E4
Signal transduction GS01 81 Glutamate receptor signaling pathway 7.3E4
GS03 55 Adenylate cyclase-activating dopamine receptor signaling pathway 3.1E3
Dopamine receptor signaling pathway 1.4E2
GS05 19 Transmembrane receptor protein kinase activity 4.4E2
GS09 111 Olfactory receptor activity 1.9E5
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GS–BC modules and gene–QT findings can be seen as a
similarity discovery over two matrices. Thus, another
future direction could be to study this problem using
machine learning approaches similar to that proposed by
Wang et al. [25].
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